Medicago appoints new Chief Financial Officer

    QUEBEC CITY, April 21 /CNW/ - Medicago Inc. (TSX-V: MDG) (the "Company"),
today announced the return of Mr. Pierre Labbé as Chief Financial Officer on a
full-time basis, effective May 5, 2008. Concurrent with his appointment, the
Company has granted Mr. Labbé 200,000 stock options at an exercise price of
$0.66, vested over a period of five years.
    "We are very pleased to welcome back Pierre Labbé. He is a seasoned
executive who will be able to contribute immediately due to his understanding
of our Company, knowledge of the life sciences sector and his public company
background," said Andy Sheldon, President & CEO of Medicago. "His appointment
strengthens our experienced senior management team and addresses the increased
demands on strategic planning and capital markets activities as we build the
Company and execute our growth strategy. I would like to take this opportunity
to thank Vincent Bélanger who has acted as temporary Chief Financial Officer
at Medicago for the last year. We are grateful for his contribution and
efforts and wish him luck with his future endeavours,"
    Pierre Labbé is a Chartered Accountant with over 20 years of financial
experience. He was most recently Vice President and Chief Financial Officer of
Plexmar Resources Inc. (TSX-V: PLE). Prior to Plexmar, Mr. Labbé spent three
years as Vice President, Chief Financial Officer and Secretary of Medicago. He
served as CFO of Sequoia Minerals Inc. and Mazarin Inc. from March 2000 to
December 2003. Prior to March 2000, Mr. Labbé held management positions in
accounting and finance with Agrinove, an agrifood cooperative and Coopers &
Lybrand, now PricewaterhouseCoopers LLP where he was involved in many
acquisitions and public financing projects. He has been Director of Advitech
Inc. (TSX-V: AVI) since May 11, 2007. He holds a degree in Business
Administration and Accounting Sciences from Université Laval. He is a member
of the Ordre des comptables agréés du Québec and of the Canadian Institute of
Chartered Accountants.
    The Company also announced that pursuant to the terms and conditions of
its stock option plan, Dr. Louis Vezina, Chief Scientific Officer, will
receive 38,444 stock options as part of his annual bonus program. Nathalie
Landry and Frédéric Ors will also receive 30,000 and 60,000 stock options,
respectively, following their appointment as Vice-President at Medicago. The
stock options were issued at an exercise price of $0.66 and expire in five
years.
    All of the above grants of options are subject to the shareholders
approval of a proposed increase in the number of shares available for options
grant under the stock option plan of Medicago. Management is seeking to obtain
directors and shareholders approval in respect of this proposed amendment to
the stock option plan of Medicago.

    About Medicago Inc.

    Medicago is committed to provide highly effective and affordable vaccines
based on proprietary Virus-Like Particle (VLP) and manufacturing technologies.
Medicago is developing VLP vaccines to protect against H5N1 pandemic
influenza, using a transient expression system which produces recombinant
vaccine antigens in non-transgenic plants. This technology has potential to
offer advantages of speed and cost over competitive technologies. It could
deliver a vaccine for testing in about a month after the identification and
reception of genetic sequences from a pandemic strain. This production time
frame has the potential to allow vaccination of the population before the
first wave of a pandemic strikes and to supply large volumes of vaccine
antigens to the world market. Additional information about Medicago is
available at www.medicago.com.

    Forward-Looking Statements

    This press release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The forward-looking
statements involve risks and uncertainties. Actual results could differ
materially from those projected herein. The Company disclaims any obligation
to update these forward-looking statements.

    The TSX Venture Exchange assumes no responsibility for the content or
    accuracy of this press release

    %SEDAR: 00023641EF

For further information: Medicago Inc.: Andy Sheldon, President and CEO,
(418) 658-9393; The Equicom Group Inc.: Arianna Vanin, Investor Relations,
(514) 844-4680, avanin@equicomgroup.com